Read Heather Donaghy’s (World ADC Beacon) review of the toxicities of ADCs which has been published in mAbs.
Three new compounds have recently initiated their first phase I trials and have been added to database:
Welcome to the 2nd World ADC Trials Intelligence Monthly Digest.
I have decided to send out June’s digest a little early so that you can read it on the plane to ASCO.
Welcome to the 3rd World ADC Trials Intelligence Monthly Digest.
We’ve been working hard this month to ensure that all the new data from the ASCO abstracts are added to Beacon and where possible we’ve linked the poster presentations.
As promised, this month’s digest focuses on the ASCO Annual Meeting, 2015.
New Clinical Trials for June
New compounds that have recently initiated their first phase I trials and have been added to Beacon:
Interestingly, the most encouraging ADC results from this year’s ASCO come from ADCs targeting solid tumours. This may reflect the clinical progression of a new generation of ADCs utilising superior targets; or better identification of the patients likely to show clinical benefit.
In this digest, I go through the different disease indications and present the novel data from ASCO.
This month’s digest provides you with a complete picture of all the ADCs in current clinical development. It was inspired by a request for more information from one of our users, and we felt it would be of general interest to the ADC community.
This month we’ve been working hard on a review of the reported toxicities of ADCs. This is the first in our series of Beacon Perspectives, which is exclusive to Beacon users and is available as a separate attachment.
This is the first in our series of Beacon Perspectives, which are exclusively available to Beacon users. They will be published approximately twice a year and will provide more in depth analysis of hot topics for ADCs.
December’s digest is packed full of conference abstracts.
We’ve included links to the abstracts on the conference website, to save you time in your meeting preparation.